Nuveen LLC Takes Position in Repligen Corporation $RGEN

Key Points

• Nuveen LLC has acquired a new position in Repligen Corporation, purchasing 279,287 shares valued at approximately $35.5 million, representing about 0.50% of the company.
• Analysts' ratings for Repligen show a consensus rating of "Moderate Buy" with a target price averaging $169.45, though some have recently downgraded their targets.
• Repligen reported a 14.8% increase in revenue year-over-year to $182.37 million, despite missing EPS estimates by $0.03 in its latest quarterly earnings.

Nuveen LLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 279,287 shares of the biotechnology company's stock, valued at approximately $35,536,000. Nuveen LLC owned 0.50% of Repligen at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Raiffeisen Bank International AG bought a new stake in Repligen in the fourth quarter valued at $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Repligen during the fourth quarter worth $40,000. Signaturefd LLC grew its holdings in shares of Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares during the last quarter. Center for Financial Planning Inc. grew its holdings in shares of Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 332 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.20% of the company's stock.

Repligen Trading Down 1.6%

Shares of Repligen stock traded down $1.94 during trading on Wednesday, hitting $121.56. 735,985 shares of the company were exchanged, compared to its average volume of 780,342. The firm has a market capitalization of $6.84 billion, a P/E ratio of -486.22, a price-to-earnings-growth ratio of 2.28 and a beta of 1.05. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The firm's fifty day moving average price is $122.16 and its 200 day moving average price is $132.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on RGEN. Barclays began coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price on the stock. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Evercore ISI decreased their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. HC Wainwright reiterated a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Finally, Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $169.45.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.